Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Date:10/24/2011

inal Products for Human Use ("CHMP") in regards to CTI's MAA for pixantrone to treat relapsed or refractory aggressive NHL. Potential recommendation in the first quarter of 2012.
  • Requested meeting with the FDA to discuss the protocol for the phase III clinical trial of tosedostat to treat relapsed or refractory myelodysplatic syndrome ("MDS").

  • For the quarter ended September 30, 2011, total operating expenses were $15.3 million compared to $13.0 million for the same period in 2010. Net loss attributable to common shareholders was $29.7 million ($0.16 per share) for the quarter ended September 30, 2011 compared to a net loss attributable to common shareholders of $15.6 million ($0.13 per share) for the same period in 2010. The increase in net loss attributable to our common shareholders is mainly due to $13.0 million in non-cash deemed dividends on preferred stock issuances and a $2.4 million increase in research and development expenses primarily associated with the pixantrone PIX306 clinical study.

    For the nine months ended September 30, 2011, total operating expenses declined to $52.3 million, which included a one-time upfront payment of $5.0 million related to the licensing of tosedostat from Chroma Therapeutics Ltd., compared to $58.8 million for the same period in 2010.  Net loss attributable to common shareholders was $103.2 million ($0.62 per share), compared to a net loss attributable to common shareholders of $113.4 million ($1.03 per share) for the same period in 2010. For the nine month period, the decrease in net loss is mainly due to a decrease in selling, general and administrative expenses.  

    CTI had approximately $45.2 million in cash and cash equivalents as of September 30, 2011, which does not include approximately $8.2 million in other proceeds received in October 2011 in connection with the settlement of a lawsuit. Conference Call InformationOn Tuesday, October 25, 2011, at 8:30 a.m. E
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... 22, 2014 METTLER TOLEDO is ... pallet measuring device CNS110 ScanTape™ . Replacing ... entry, offering greater ease and accuracy for transport ... can significantly enhance productivity—an important benefit for load ... volume equals profits. , Usable at any ...
    (Date:9/21/2014)... at the University of Basel in Switzerland have ... a charged molecule for the first time. These ... measurements of molecular properties and may also contribute ... technology. The results were published in the scientific ... study of the interaction between matter and light, ...
    (Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
    (Date:9/19/2014)... -- InterMune, Inc. (Nasdaq: ITMN ) today announced ... settle the litigation in the Delaware Court of Chancery ... as of August 22, 2014, among Roche Holdings, Inc., ... of the Memorandum of Understanding, the Company agreed to ... exhibit reflecting the amendment to the Company,s Schedule 14D-9 ...
    Breaking Biology Technology:ScanTape™ Handheld Dimensioner Increases Processing Volume 2Uncovering the forbidden side of molecules 2Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
    ... , CAMBRIDGE, Mass., Dec. ... leaders in technology development and product integration in cleantech, ... for technology abstracts and business presentations. , Now in ... Nano Science and Technology Institute (NSTI), and the Clean ...
    ... RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- ... EMDY), a leading,producer and distributor of infant and children,s formula, ... Company will be featured,in the Spring issue of US Food ... 250,000 executives in the food and beverage industry. , ...
    ... , ... through,extraordinary times; markets are in turmoil and uncertainty is part ... industry has been,relatively immune to the economic downturn, because illness ... midst of the difficult times this year, the pharmaceutical,giant Johnson ...
    Cached Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
    (Date:9/21/2014)... San Diego, have developed a program that predicts the ... genes based on sequences of DNA. They describe their ... embryonic cells in a paper published in Nature ... cells have the same blueprint, the same DNA, although ... of the report. "Skin cells protect, nerve cells send ...
    (Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
    (Date:9/21/2014)... researchers has developed a protein therapy that disrupts the ... original tumor sites, travel through the blood stream and ... This process, known as metastasis, can cause cancer to ... patients who succumb to cancer fall prey to metastatic ... professor of bioengineering who describes a new therapeutic approach ...
    Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
    ... Island Hospital researcher has found that the use of electronic ... on the demand for drug treatment programs and how prescribers ... Traci C. Green, Ph.D., MSc, research scientist in Rhode Island ... advance of print in the journal Pain Medicine . ...
    ... Aug. 16, 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ) ... their Safe Storage and Access Lockers as other major companies ... "When a company as large as Amazon introduces ... educate the public about the usefulness and benefits of the ...
    ... countries will experience more extreme floods and droughts, in ... paper out today in the journal Nature . ... rain band responding to greenhouse warming. The South Pacific ... Southern Hemisphere spanning the Pacific from south of the ...
    Cached Biology News:RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse 2RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse 3Medbox Safe Storage and Access Lockers Gaining Popularity 2Warming causes more extreme shifts of the Southern Hemisphere's largest rain band 2
    ... Agencourt offers single pass sequencing of ... is fueled by our high performance ... million Phred20 bases per day. The ... pass sequencing customers are rapid turnaround, ...
    ... Facility , Galaxy LIMS, Sophisticated Bioinformatics , ... scientists ,We offer individual sample sequencing of ... for single or double strand publication quality. ... DNA of interest is 1.3 to 7 ...
    ... sequencing of individual research samples, including PCR ... Agencourt's world-class, high performance sequencing pipeline processes ... The key benefits of Agencourt's QuickLane ... 48 hour sample turnaround, industry leading sequence ...
    Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
    Biology Products: